You are here: Industry Insights > BTK

News List

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China prnasia
August 11, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting ...
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 21, 2021
InnoCare announced the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on MPresents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 18, 2021
InnoCare announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS americanpharmaceuticalreview
April 19, 2021
Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting showing that the investigational Bruton’s tyrosine kinase (BTK) ...
12-Month Below-the-Knee Data with MedAlliance's SELUTION SLR™ Presented as Late Breaking Trial at LINC europeanpharmaceuticalreview
January 29, 2021
12-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021.
Calquence tops Imbruvica in chronic lymphocytic leukaemia study pharmatimes
January 26, 2021
AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) hit the primary endpoint in a Phase III study in chronic lymphocytic leukaemia (CLL).
Innocare Gets Approval from NMPA for Orelabrutinib contractpharma
January 08, 2021
Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib, an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death.
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold americanpharmaceuticalreview
September 07, 2020
Abbott has announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit™ BTK Everolimus Eluting Resorbable Scaffold System.
Enrolment initiated in World's First RCT with Sirolimus Coated Balloon for the treatment of Below-the-Knee (BTK) Peripheral Artery Disease prnasia
August 27, 2020
Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE BTK trial (Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in T
Potential cytokine storm treatment identified for severe COVID-19 patients europeanpharmaceuticalreview
June 09, 2020
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.

Previous page 1 2 Next page